All In Biotech

Investigational drug · Phase 2

QLC1401

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Breast Cancer, Advanced ER+/HER2- Breast Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "QLC1401"

First trial start

2025

Sep 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QLC1401", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Breast Cancer
  • Advanced ER+/HER2- Breast Cancer

Approved drugs for the same conditions: Breast cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "QLC1401" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Breast Cancer

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • UtidelonePhase 38 trials

    Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma

  • KN026PlacboPhase 37 trials

    Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer

  • PalazestrantOP-1250Phase 32 trials

    Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

  • RYZ101Phase 32 trials

    RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer

  • XZP-3287Phase 32 trials

    Xuanzhu Biopharmaceutical Co., Ltd. · Advanced Breast Cancer

  • ZovegalisibPhase 31 trial

    Relay Therapeutics, Inc. · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor

  • MHB039APhase 24 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.